Dasatinib is safe and effective in patients with previously untreated chronic myelogenous leukemia in chronic phase

被引：0
|
作者：
Quintas-Cardama, A.
Kantarjian, H.
OBrien, S.
Jones, D.
Borthakur, G.
Nicaise, C.
Cortes, J.
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0360
引用
收藏
页码：129 / 129
页数：1
相关论文
共 50 条
  • [21] Chronic myelogenous leukemia in chronic phase transforming into acute leukemia under treatment with dasatinib 4 months after diagnosis
    Nakamura, Yukitsugu
    Tokita, Katsuya
    Nagasawa, Fusako
    Takahashi, Wataru
    Nakamura, Yuko
    Sasaki, Ko
    Ichikawa, Motoshi
    Mitani, Kinuko
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (03) : 348 - 353
  • [22] Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia
    Giles, FJ
    Wong, GC
    Clark, SJ
    Pierce, S
    Kantarjian, HM
    Keating, MJ
    LEUKEMIA & LYMPHOMA, 2000, 37 (1-2) : 87 - 95
  • [23] Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance
    Le Coutre, Philipp
    Giles, Francis J.
    Apperley, Jane
    Ottmann, Oliver G.
    Gattermann, Norbert
    O'Brien, Stephen G.
    Kuliczkowski, Kazimierz
    Larson, Richard A.
    Kim, Dong-Wook
    Haque, Ariful
    Gallagher, Neil
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 145A - 145A
  • [24] Chronic myelogenous leukemia in chronic phase.
    Kurzrock R.
    Kantarjian H.
    Talpaz M.
    Current Treatment Options in Oncology, 2001, 2 (3) : 245 - 252
  • [25] Bleeding diathesis in patients (pts) with chronic myelogenous leukemia receiving dasatinib therapy
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Ravandi, Farhad
    Burger, Jan
    Borthakur, Gautam
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 869A - 869A
  • [26] Association of Pleural Effusion and Bleeding in Patients with Chronic Myelogenous Leukemia Receiving Dasatinib
    Qufntas-Cardama, Alfonso
    Kantarjian, Hagop M.
    O'Brien, Susan
    Ravandi, Farhad
    Ferrajoli, Alessandra
    Garcia-Manero, Guillermo
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 735 - 735
  • [27] The Efficacy of Tolvaptan on Dasatinib induced Pleural Effusions in Patients with Chronic Myelogenous Leukemia
    Aoyama, Rie
    Onodera, Kenta
    Murai, Kouji
    Tokita, Yukichi
    Tsukada, Yayoi
    Asai, Kuniya
    Shimizu, Wataru
    Manabe, Yoko
    Tanaka, Jun
    Harada, Kazumasa
    JOURNAL OF CARDIAC FAILURE, 2016, 22 (09) : S170 - S170
  • [28] EFFICACY OF NILOTINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED, PREVIOUSLY UNTREATED PHILADELPHIA CHROMOSOME (PH)-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN EARLY CHRONIC PHASE (CML-CP)
    Cortes, J.
    Jones, D.
    O'Brien, S.
    Ferrajoli, A.
    Borhtakur, G.
    Burger, J.
    Wierda, W.
    Garcia-Manero, G.
    Letvak, L.
    Kantarjian, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 48 - 48
  • [29] Efficacy of Nilotinib in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP)
    Cortes, Jorge
    O'Brien, Susan
    Jones, Dan
    Jabbour, Elias
    Konopleva, Marina
    Ferrajoli, Alessandra
    Kadia, Tapan
    Borthakur, Gautam
    Stigliano, Denise
    Shan, Jenny
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 144 - 145
  • [30] Obinutuzumab for previously untreated chronic lymphocytic leukemia
    不详
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (04): : 118 - 120
12345